Global Iohexol API Market Presumed to Reach US$ 885.41 Mn by 2028 with a CAGR of 6.91%
Iohexol was first listed in Norway and Sweden in 1982. It is a kind of second-generation non-ionic monomeric contrast agent. Iopromide, Iomeprol, etc. Iohexol has low osmotic pressure, low toxicity to the nervous system, low contrast density, and good tolerance. It can be used for angiography, subarachnoid angiography, coronary angiography, spinal cord and femoral joints, urology angiography, and enhanced CT scanning. Etc., is the "gold standard" for evaluating various X-ray contrast agents in the medical community.
View full press release